Sramana Mitra: What you just said is very interesting from a computer science point of view. So far, it seems like pharma has been developing drugs with clinical trials that have relatively small numbers of people whose data is going into trial input. The big data opportunity is to do this at a much higher scale.
You can collect data from millions of patients in the process of figuring out what works, whys, on what segments, and what kinds of biometric characterization. All of that is very viable. So far, it hasn’t been that viable. So far, you take small samples and you extrapolate. But it’s all becoming very viable and potentially, even cost effective to do this at scale. Could you comment on this trend? >>>
Sramana Mitra: You put in context what might happen with the existing workflow of the drug development as we introduce more capability from a scalability point of view. Instead of a drug going through three or four stages of clinical trials, maybe it will go through five or ten stages of clinical trials going into broader and broader populations. But the data has to come in, so that there is a continuous monitoring of what is the impact of the drug on various populations.
Tarek Sherif: By the way, this isn’t just from a negative perspective. You can look at it from a positive perspective. You bring a drug to market and you see that it has positive side effects or it impacts patients who have a different diseases. We see drug repurposing all the time where it was designed for one thing, but it actually has an impact on something else. Those are the kinds of effects that you want. >>>
Sramana Mitra: If you look at all the things that they’ve been doing and all the product roadmap announcements that they’ve made, they’re going into clinical trials in a big way. That’s why I asked you the question. Historically, they have come out of CRM but clinical research organizations and clinical trials has been one of their big target areas. Are you starting to see them in deals?
Tarek Sherif: No, their marketing position is much stronger than the reality of where we see them. They have done a good job on electronic trial master file (eTMF), which again is document management. They’ve had a little bit of success in clinical trial management systems (Clinical Trial Management Systemz). We don’t see them at all in the electronic data capture (EDC) market, which is really the bulk of our business currently. >>>
Sramana Mitra: We have a little company within the 1Mby1M program called CleaningUp. Their discovery is that, as you said, a huge percentage of the workflow of drug development is still on paper and not digital. Especially when trials are held in international locations, people fill out papers.
They’re trying to transform that process into filling out iPads. They’re seeing a good deal of success in that world. It’s another niche phase of the market, but this is a company that is focusing on the part of the industry that has not moved online and it’s helping them move online. >>>
The clinical data domain is going through major changes and is full of opportunities. This discussion delves into the industry with one of its biggest players.
Sramana Mitra: Let’s introduce our audience to you as well as Medidata.
Tarek Sherif: I’m Tarek Sherif. I’m a Co-Founder, the CEO, and Chairman of Medidata Solutions. We’re a New York-based company but global in operations. We’re focused on helping life sciences companies – biotech, large pharma, and medical device companies as well as academic organizations. >>>
Sramana Mitra: How do you charge your clients?
Carol Clayton: If you are a provider agency and you’re going to buy a performance solution like Relias, we’re going to look at your enrolled population. It’s generally because in those arrangements, the provider is being paid per member per month (PMPM) to manage that. >>>
Sramana Mitra: Let’s take a hospital that has these kinds of behaviors. Could you take us through a live customer and what you have been able to do? What kind of numbers are you seeing?
Carol Clayton: I’m going to use a different model. I won’t use a hospital system. I’m going to use a behavioral health system. In the state of Oklahoma, they have implemented a behavioral health home model for their Medicaid beneficiaries. That is for behavioral health agencies to provide directly or coordinate care for persons with behavioral health disorders who also have chronic health conditions. >>>
Carol explains certain SaaS-enabled BPO opportunities within the value-based healthcare domain.
Sramana Mitra: Let’s start by introducing our audience to yourself as well as to Relias.
Carol Clayton: I’m a psychologist by training. I worked as the translational neuroscientist at Relias. Relias is a healthcare technology company with footprints specifically in the space of using online tools for training and competency development in the healthcare space. They are evolving their tools and solutions to assist healthcare providers and organizations with better use of data. It also links data to learning so that organizations can be data-driven in looking at their performance within their healthcare vertical. >>>